NL-OMON38584招募中不适用
Dose-to-target of etanercept treatment: a dose-tapering randomized controlled trial in patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. - Dose-to-target of etanercept treatment in rheumatic diseases.
Jan van Breemen Instituut0 个研究点目标入组 250 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Diagnosis: Rheumatoid Arthritis (according to the American College of Rheumatology 1987 criteria), or Psoriatic Arthritis (according to the Classification of Psoriatic Arthritis criteria) or Ankylosing spondylitis (according to the 1984 New York Criteria).
- •Treatment with etanercept 50 mg subcutaneously (SC) weekly (or 25 mg SC twice weekly) for at least 6 subsequent months.
- •Minimal Disease Activity (MDA): Outcome Measures in Rheumatology (OMERACT) MDA criteria for RA, MDA criteria for PsA which are defined in collaboration with the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Ankylosing Spondylitis Disease Activity Score (ASDAS), using C-reactive protein (CRP), inactive or moderate disease activity.
- •Written informed consent.
排除标准
- •Planned reasons for treatment discontinuation
研究者
相似试验
招募中
不适用
Dose-to-target of etanercept treatment: a dose-tapering randomized controlled trial in patients with juvenile idiopathic arthritis in patients age 12 years and older.10003816juvenile idiopathic arthritisNL-OMON40793Jan van Breemen Instituut40
尚未招募
不适用
Dose-to-target of etanercept treatment in patients with juvenile idiopathic arthritis in patients age 12 years and older.etanercept, juvenile idiopathic arthritis, dose tapering, discontinuationNL-OMON20690Jan van Breemen Instituut, Reade40
尚未招募
不适用
Dose-to-target of etanercept treatment in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.Etanercept, dose-to-target, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, personalized medicineNL-OMON24861Jan van Breemen Research Institute | Reade250
进行中（未招募）
1 期
Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Subjects Who Have Achieved a Stable Low Disease Activity-state (DOSERA) - DOSERARheumatoid Arthritis (RA) patients who are on Etanercept (ETN) treatment and are in remission or in a Low Disease Activity (LDA) stateMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2007-006657-63-HUWyeth Pharmaceuticals France186
进行中（未招募）
不适用
Study comparing the effect on disease activity when reducing or discontinuing Etanercept in subjects with Rheumatoid Arthritis (RA) (DOSERA)EUCTR2007-006657-63-DKPfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom72